BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies
BeiGene Ltd. (BGNE) announced that it has inked a new deal with Singlomics Biopharmaceuticals Co. for developing, manufacturing and commercializing various anti-COVID-19 antibodies, including DXP-593 and DXP-604. Under the terms of this collaboration, BeiGene will be responsible for these antibodies outside of greater China.
It is expected that a Phase 1 randomized, double-blind, and placebo-controlled clinical trial will be started. The enrollment of nearly 30 healthy subjects for the trial will likely begin in September. The participant recruitment for the Phase 1/2 multinational trial